A REVIEW ON ARTIFICIAL BLOOD: A SOURCE WE NEED

Authors

  • Krishna Veni R Department of Bio-Engineering, School of Engineering, Vels University, Chennai - 600 117, Tamil Nadu, India.
  • Brindha Devi P Department of Bio-Engineering, School of Engineering, Vels University, Chennai - 600 117, Tamil Nadu, India.
  • Ivo Romauld S Department of Bio-Engineering, School of Engineering, Vels University, Chennai - 600 117, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i9.18960

Keywords:

Artificial blood, Blood transfusion, Plastic blood, Perfluorocarbons, Hemoglobin-based oxygen carriers, Cross matching, Shelf life

Abstract

Blood is a liquid tissue, in which abundant chemical factors and millions of different cells are dissolved. It is one of the most demanding sources in clinical and medical aspects. The issues and cost of human blood collection and storage directed this procedure toward the use of alternative blood. Thus, came an invention of artificial blood and blood substitutes. These alternative blood or blood substitute is a substance which is made to play as a substitute of erythrocytes. Thus, the main objective is to replace the normal human blood with artificial blood substitutes in the place of blood transfusion during surgeries and organ transfusion. Two major and focused blood substitutes in pharmaceutical aspects are perfluorocarbons and hemoglobin-based oxygen carriers (HBOC's). Among these HBOCs vaguely resemble normal human blood. These blood substitutes are to allow flow through the blood stream to carry the oxygen and supply it to heart and other parts of the blood. They are used to fill the lost fluid volume. They are also called as plastic blood with iron atom as the base. They are found to serve as a good oxygen carrier. The results showed by these products are discussed, and they proved that they can act as a blood substitute and also they can reach the human tissue easier than erythrocytes and can control oxygen directly. However, these artificial blood products are being processed in research laboratories for good outcome. Their important functions are oxygen carrying capacity and to replace the lost blood volume in the human body. Their special features are survivability over a wider range of temperatures, eliminating cross matching, cost efficient, pathogen free, long shelf life, minimal side effects. Thus, artificial blood products are really a good alternative source which we need for replacing normal human blood.

Downloads

Download data is not yet available.

Author Biography

Krishna Veni R, Department of Bio-Engineering, School of Engineering, Vels University, Chennai - 600 117, Tamil Nadu, India.

Department of Bio-Engineering

References

Keyhanian SH, Ebrahimifard M, Zandi M. Investigation on artificial blood or substitute blood replace the natural blood. Iran J Ped Hematol Oncol 2014;4(2):72-7.

Anilkumar D, Sudarshan P, Ragavan K, Niranjan Babu M. A review of artificial blood. Int J Pharm Chem Biol Sci 2015;5(2):477-80.

Mohankrishna L, Balammal G, Aruna G. A review on arrtificial blood. Int J Biopharm 2011;2(2):80-8.

Sharma A, Arora S, Grewal P, Dhillon V, Kumar V. Recent innovations in delivery of artificial blood substitute: A review. Int J Appl Pharm 2011;3(2):1-5.

Neelam S, Semwal BC, Krishna M, Ruqsana K, Shravan P. Artificial blood: A tool for survaival of human. Int Res J Pharm 2012;3(5):119-23.

Phadke NM, Phadtare DG, Saudagar RB. Artificial blood: A life saving tool. World J Pharm Pharm Sci 2014;3(8):2146-55.

Patel DM. Artificial Blood. Available From: https://www.slideshare.net. [Last accessed on 2015 Feb 11]..

Sarkar S. Artificial blood. Indian Soc Crit Care Med 2008;12(3):140-4.

Mozafari M, Ramedani A, Yazdanpanah A. Artificial blood – A game changer for future medicine. J Blood Disord Transfus 2015;6(5):1-2.

Varnado CL, Mollan TL, Birukou I, Smith BJ, Henderson DP, Olson JS. Development of recombinant hemoglobin-based oxygen carriers. Antioxid Redox Signal 2013;18(17):2314-28.

Henkel-Honke T, Oleck M. Artificial oxygen carriers: A current review. AANA J 2007;75(3):205-11.

Likhitha D, Shankar M, Kavya Lalitha S, Supriya T, Niranjan Babu M. Blood substituents an overview. Acta Biomed Sci 2016;3(4):187-92.

Moradi S, Jahanian-Najafabadi A, Roudkenar MH. Artificial blood substitutes: First steps on the long route to clinical utility. Clin Med Insights Blood Disord 2016;9:33-41.

Sharma AR, Arora S, Grewal P, Dhillon V, Kumar V. Recent innovations in delivery of artificial blood substitute: A review. Int J Appl Pharm 2011;3(2):1-5.

Chang TM. From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond. Artif Cells Blood Substit Immobil Biotechnol 2012;40(3):197-9.

Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009;94(12):1777-8.

Abdulzahra MS, Al-Hakeim HK, Ridha MM. Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian J Transfus Sci 2011;5(2):127-31.

Salih MK, Mosawy WF. Evaluation some consequences of thalassemia major in splenectomized and non-splenectomized Iraqi patients. Int J Pharm Pharm Sci 2013;5:385-8.

Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: Systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ 2015;350:h1354.

Bennett-Guerrero E, Zhao Y, O’Brien SM, Ferguson TB Jr., Peterson ED, Gammie JS, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010;304(14):1568-75.

Belien J, Force H. Supply chain management of blood products: A literature review. Eur J Oper Res 2012;217(1):1-6.

Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, et al. Health care-associated infection after red blood cell transfusion: A systematic review and meta-analysis. JAMA 2014;311(13):1317-26.

Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013;381(9880):1845-54.

Bednall TC, Bove LL. Donating blood: A meta-analytic review of self-reported motivators and deterrents. Transfus Med Rev 2011;25(4):317-34.

Carson JL, Carless PA, Hébert PC. Outcomes using lower vs. higher hemoglobin thresholds for red blood cell transfusion. JAMA 2013;309(1):83-4.

Gaurav B, Arvind G, Hemlata G, Kapil A. Periodontal regeneration by stem cells therapy. Int J Pharm Pharm Sci 2012;4:421-5.

Published

01-09-2017

How to Cite

R, K. V., B. D. P, and I. R. S. “A REVIEW ON ARTIFICIAL BLOOD: A SOURCE WE NEED”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 9, Sept. 2017, pp. 38-43, doi:10.22159/ajpcr.2017.v10i9.18960.

Issue

Section

Review Article(s)